Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

AIDS

Volumn 18, Issue 6, 2004, Pages 897-907

  Wire, Mary Beth ^a   Ballow, Charles ^b   Preston, Sandra L ^c   Hendrix, Craig W ^d   Piliero, Peter J ^c   Lou, Yu ^a   Stein, Daniel S ^a  

^a GLAXOSMITHKLINE   (United States)

^b Buffalo Clinical Research Center   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Amprenavir; Antiretroviral therapy; Efavirenz; GW433908; Pharmacokinetics; Ritonavir

Indexed keywords

AMPRENAVIR PHOSPHATE; EFAVIRENZ; RITONAVIR;

ADULT; APPETITE DISORDER; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERHIDROSIS; MALE; MENTAL CONCENTRATION; NAUSEA; NECK PAIN; NEUROLOGIC DISEASE; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; THROAT DISEASE; VOMITING;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CARBAMATES; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OXAZINES; PHOSPHORIC ACID ESTERS; PRODRUGS; RITONAVIR; SULFONAMIDES; TRIGLYCERIDES;

EID: 2142700048     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404090-00007     Document Type: Article

References (34)

1. Spaltenstein A, Baker C, Gray-Nunez Y, Kaldor I, Kazmierski W, Reynolds D, et al. Highly polar, water-soluble prodrugs of amprenavir: a new approach toward a more compact dosing regimen. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January 2000 [abstract 505].
2. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract 916].
3. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract 917].
4. th Annual Meeting of the Infectious Disease Society of America. Philadelphia, November 1999 [abstract 343].
5. Wood R, Arasteh K, Pollard R, Kaur P, Naderer O, Wire MB. GW433908, a novel prodrug of the HIV protease inhibitor (PI) amprenavir (APV): safety, efficacy, and pharmacokinetics (PK) (APV20001). Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 333].
6. Nadler J, Rodriguez-French A, Millard J, Wannamaker P. The NEAT Study: GW433908 efficacy and safety in ART-naïve subjects, final 48-week analysis. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 177].
7. DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The Context Study: efficacy and safety of GW433908/RTV in Pl-experienced subjects with virological failure (24 week results). Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 178].
8. Schurmann D, Gathe J, Sanne I, Wood R. Efficacy and safety of GW433908/ritonavir once daily in therapy-naïve subjects, 48 week results: the SOLO Study. Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, November 2002 [abstract PL14.4].
9. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001, 33:865-872.
10. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001, 15: 1369-1377.
11. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
12. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865-1873.
13. Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick M, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000, 30:313-318.
14. Merck & Co. Inc. Crixivan (indinavir) complete prescribing information. Whitehouse Station, New Jersey: Merck; 2002.
15. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003, 63:769-802.
16. Preston S, Piliero P, O'Mara E, Mummaneni V, Randall D, Morvillo C, et al. Evaluation of the steady-state interaction between atazanavir (ATV) and efavirenz (EFV). Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 443].
17. Piscitelli S, Bechtel C, Sadler B, Falloon J, and the Intramural AIDS Program. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January 2000 [abstract 78].
18. O'Mara E, Agarwala S, Randall D, Geraldes M, Stoltz R, Mummaneni V. Steady-state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) and ritonavir (RTV) in healthy subjects. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 444].
19. Aarnoutse RE, Grintjes KJT, Telgt DSC, Stek M, Hugen PWH, Reiss P, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 2002, 71:57-67.
20. National Institute of Allergy and Infectious Diseases, Division of AIDS, AIDS Clinical Trial Group (ACTG). Toxicity table for grading severity of adult adverse experiences. 1992.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult treatment Panel III). JAMA 2001, 285:2486-2497.
22. Wood R, Wire MB, Lancaster CT, Lou Y, Orrell C, Scott TR. An assessment of plasma amprenavir (APV) pharmacokinetics (PK) following administration of Agenerase (APV) and low dose ritonavir (RTV) QD in combination with efavirenz (EFV) in HIV-infected adult subjects (COL30500). Third International Workshop on Clinical Pharmacology of HIV Therapy. Washington DC, April 2002 [abstract 2.6].
23. st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 2001 [abstract 1924].
24. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002, 46:746-754.
25. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract 327].
26. Veldkamp AI, van Heeswijk RPG, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001, 27:344-349.
27. Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother 2001, 45:2710-2715.
28. Van Heeswijk RPG, Veldkamp AI, Hoetelmans RMW, Mulder JW, Schreij G, Hsu A, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 infected individuals. AIDS 1999, 13:F95-F99.
29. Bristol-Myers Squibb. Sustiva (efavirenz) complete prescribing information. Princeton, New Jersey: Bristol-Myers Squibb; 2002.
30. Abbott Laboratories. Norvir (ritonavir) complete prescribing information. Abbott Park, Illinois: Abbott Laboratories; 2002.
31. Danner S, Carr A, Leonard J, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
32. Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001, 45:30-37.
33. Pedneault L, Brothers C, Pagano G, Tymkewycz P, Yeo J, Millard J, et al. Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. Clin Ther 2000, 22:1378-1394.
34. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimcrob Agents Chemother 1997, 41:898-905.